European Commission Approves KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
Dateline City:
KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the first-line
treatment of metastatic non-small cell lung cancer (NSCLC) in adults
whose tumors have high PD-L1 expression (tumor proportion score [TPS] of
50 percent or more) with no EGFR or ALK positive tumor mutations.Language:
EnglishContact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NSCLC NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals